Cosmos Health, Inc. (Nasdaq: COSM) $COSM is a diversified, vertically integrated global healthcare group. COSM owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), COSM manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.
COSM also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, COSM has established R&D partnerships targeting major health disorders such as obesity, diabetes and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products.
COSM has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, COSM is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.
State-of-the-Art Capsule Production Line for New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
On June 9th COSM announced that its wholly-owned subsidiary, Cana Laboratories, has inaugurated a new, state-of-the-art capsule production line and secured an additional contract manufacturing agreement with Provident Pharmaceuticals, a specialty pharmaceutical company focused on the commercialization and marketing of niche and legacy pharmaceutical products and medical devices in specific therapeutic areas.
COSM will manufacture 385,000 units of CERTORUN® (sertraline hydrochloride) over the five-year period, at an annual production volume of 77,000 units. CERTORUN® is an antidepressant in the selective serotonin reuptake inhibitor (SSRI) class used to treat depression, anxiety, and related disorders. The product will be produced in two strengths — CERTORUN® Caps 50mg/cap (BTx30, blister 3×10) and CERTORUN® Caps 100mg/cap (BTx30, blister 3×10).
Production will take place on Cana’s newly installed ACG capsule-filling line, part of the COSM ongoing investment in upgrading and modernizing its manufacturing capabilities and capacities. ACG is one of the world’s leading suppliers of empty hard capsules and integrated pharmaceutical manufacturing equipment.
This latest order builds on the growing COSM relationship with Provident, following a series of contract manufacturing agreements for products including DE3-SOLE®, MIOREL®, CALCIFOLIN®, and DEXA-DOSE®.
Completed Acquisition of Strategic Intellectual Property, Expanding Nanotechnology Investment Initiatives
On June 8th COSM announced that its wholly owned subsidiary, Cana Laboratories S.A., has acquired ownership of international patent application WO2025108566A1 from Cloudpharm P.C., and expanded its nanotechnology investment initiatives.
KEY HIGHLIGHTS
Patent protection being pursued at national and regional levels across key international markets.
Technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development.
Expands nanotechnology investment initiatives, leveraging COSM European GMP-certified manufacturing capabilities.
Aligned with the COSM broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value.
Continued U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories
On June 5th COSM announced the U.S. launch of Oliv18™, further expanding its science-driven 18 Series nutraceutical platform into cardiovascular and antioxidant categories.
Oliv18™ expands the 18 Series with a USDA and EU organic certified, 100% solvent-free, whole olive polyphenol formulation from the Moroccan Saharan desert.
Hydroxytyrosol — the key active in Oliv18™ — is the highest ORAC polyphenol
A single 250 mg daily dose meets EFSA’s 5 mg/day hydroxytyrosol minimum dose for protection against LDL oxidation
A single daily dose equivalent to approximately 11 teaspoons of good quality extra virgin olive oil — compared to an average of half a teaspoon per day in the U.S.
COSM is targeting the multibillion cardiovascular health and antioxidant markets, initially in the United States and globally thereafter within a combined global market landscape projected to exceed $33 billion by 2035
$20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value
On June 4th COSM announced having identified approximately $20 million in assets that can be converted to liquidity without impacting the Company’s operational capabilities.
The identified assets comprise, among others, wholly owned real estate — the CosmoFarm distribution facility and Cana Laboratories manufacturing site — independently valued at approximately $15 million, a large portion of which is free of any mortgage or financial encumbrance, with options including an outright sale, sale and leaseback, or borrowing against these assets. The market value of the real estate alone exceeds the COSM current market capitalisation. In addition, COSM holds digital assets, marketable securities, and other liquid assets as part of its broader treasury strategy, which are readily monetizable.
European Investment Bank Financing Discussions for up to €25M, Eliminating 38% of Warrants with No Dilution, Reaffirming Business Growth Trajectory
On June 2nd COSM provided an update on its balance sheet and noted no known business reason for the recent decline in its share price. The COSM balance sheet is trending positively across multiple key metrics.
Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, driven by a substantial reduction in convertible note and credit facility balances
Stockholders’ equity increased by $1.4 million, or 7.6%, quarter-over-quarter
Liabilities-to-assets ratio improved by 370 basis points to 68.2% from 71.9% at year-end 2025
COSM is in discussions with the European Investment Bank (EIB) for financing of up to €25 million, reflecting up to 50% of its broader €50 million R&D initiative. If successfully concluded, this financing would represent a significant milestone for the COSM R&D platform, which is anchored by the proprietary AI-driven Cloudscreen drug repurposing technology and spans oncology, autoimmune diseases, neurology, and obesity.
4,874,126 Series B Warrants have expired unexercised, eliminating approximately 38% of total outstanding warrants with no shareholder dilution. This represents a meaningful simplification of the COSM capital structure that directly benefits existing shareholders.
COSM holds Real Estate Assets valued at over $15 Million. The market value of these assets alone exceed the Company’s current market capitalization and represent a meaningful component of the COSM asset base the Company believes is not yet reflected in its share price.
COSM has secured a financing facility of up to $300 million to support its digital assets treasury strategy. COSM has commenced investments in digital assets, with the strategy providing balance sheet diversification and a platform to explore blockchain’s practical applications in healthcare.
COSM is growing at its fastest pace in Company history — FY2025 revenue of $65.3 million was an all time annual record, up 20% year-over-year with gross profit growing 83%, followed by Q1 2026 revenue of $17.9 million, the highest in COSM history, up 31% year-over-year, with momentum continuing into Q2 2026 across all core divisions.
COSM 2026-2029 Guidance projects this trajectory to drive a structural transformation of the balance sheet: revenue growing to $200.6 million by 2029 at a 32% CAGR, gross margins expanding from 12.1% to 35.5%, Adjusted EBITDA reaching $44.2 million, operating cash flow of $24 million, a cash position of $62.9 million, and stockholders’ equity growing 402% to $92.3 million — with all convertible debt projected to be fully repaid and cash expected to exceed total debt by 2027.
Entering $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
On June 1st COSM announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company’s first entry into the animal health market.
COSM intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.
The global animal health market was estimated at approximately $68.7 billion in 2025 and is projected to reach $156.0 billion by 2033, growing at a compound annual growth rate of 11.0%, according to Grand View Research.
COSM C-Scrub Wash 4% successfully demonstrated bactericidal activity according to EN 1656:2019 and yeasticidal activity according to EN 1657:2024 following independent testing conducted by Quality Assurance & Control Systems Ltd.
For more information on $COSM visit: www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr/en/home/, www.zipdoctor.co, https://cloudscreen.gr/en/
Email: [email protected] or [email protected]
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Media ContactCompany Name: Cosmos Health, Inc. (Nasdaq: COSM),Contact Person: BDG CommunicationsEmail: Send EmailPhone: (312) 865-0026Address:141 West Jackson Blvd., Suite 4234 City: ChicagoState: IL 60604Country: United StatesWebsite: www.cosmoshealthinc.com
